Defining the risks of mesenchymal stromal cell therapy

Darwin J. Prockop, Malcolm Brenner, Willem E. Fibbe, Edwin Horwitz, Katarina Le Blanc, Donald G. Phinney, Paul J. Simmons, Luc Sensebe, Armand Keating

Research output: Contribution to journalArticlepeer-review

275 Scopus citations


We address the issue of the potential for malignant transformation of cultured mesenchymal stromal cells (MSC) commonly used in clinical cell-therapy protocols and describe the culture conditions under which tumorigenesis is likely to be an extremely uncommon event.

Original languageEnglish (US)
Pages (from-to)576-578
Number of pages3
Issue number5
StatePublished - Sep 2010


  • Cell contamination
  • Mesenchymal stem cells
  • MSCs

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Molecular Medicine


Dive into the research topics of 'Defining the risks of mesenchymal stromal cell therapy'. Together they form a unique fingerprint.

Cite this